$0.72
2.48% yesterday
Nasdaq, Nov 07, 10:15 pm CET
ISIN
US4525EP1011
Symbol
IMUX

Immunic, Inc. Stock price

$0.72
-0.16 18.34% 1M
-0.27 27.07% 6M
-0.28 28.14% YTD
-0.46 39.10% 1Y
-0.71 49.75% 3Y
-16.20 95.75% 5Y
-317.28 99.77% 10Y
-479.28 99.85% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.02 2.48%
ISIN
US4525EP1011
Symbol
IMUX
Industry

Key metrics

Basic
Market capitalization
$70.9m
Enterprise Value
$15.6m
Net debt
positive
Cash
$55.3m
Shares outstanding
98.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.1
Financial Health
Equity Ratio
45.1%
Return on Equity
-545.4%
ROCE
-308.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-105.1m | -
EBIT
$-105.3m | $-103.3m
Net Income
$-101.8m | $-73.6m
Free Cash Flow
$-90.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-12.4% | -
EBIT
-12.4% | -5.4%
Net Income
-6.9% | 26.8%
Free Cash Flow
-24.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.9
Short interest
9.8%
Employees
90
Rev per Employee
$0.0
Show more

Is Immunic, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Immunic, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Immunic, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Immunic, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Immunic, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
11% 11%
-
- Research and Development Expense 86 86
13% 13%
-
-105 -105
12% 12%
-
- Depreciation and Amortization 0.16 0.16
33% 33%
-
EBIT (Operating Income) EBIT -105 -105
12% 12%
-
Net Profit -102 -102
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunic, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunic, Inc. Stock News

Positive
Proactive Investors
about 4 hours ago
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. Vitt discussed the progress of Immunic's lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for multiple sclerosis, which are fully enrolled and expected to report data at the end ...
Neutral
PRNewsWire
10 days ago
NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: November 3-5: BIO-Europe. Daniel Vitt, Ph.D.
AD HOC NEWS
11 days ago
Immunic AG / US4525EP1011
More Immunic, Inc. News

Company Profile

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

Head office United States
CEO Daniel Vitt
Employees 90
Founded 2003
Website imux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today